






## ORIGINAL RESEARCH

## Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies

Sophie I E Liem <sup>1</sup>, Sam Neppelenbroek <sup>1</sup>, Cynthia M Fehres,<sup>1</sup> Brigitte A Wevers,<sup>2</sup> René E M Toes <sup>1</sup>, Cornelia F Allaart,<sup>1</sup> Tom W J Huizinga <sup>1</sup>, Hans Ulrich Scherer <sup>1</sup>, Jeska K De Vries-Bouwstra<sup>1</sup>

**To cite:** Liem SIE, Neppelenbroek S, Fehres CM, et al. Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies. *RMD Open* 2023;**9**:e002827. doi:10.1136/rmdopen-2022-002827

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/rmdopen-2022-002827>).

Received 1 November 2022  
Accepted 11 January 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

<sup>2</sup>Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands

**Correspondence to**  
Sophie I E Liem;  
S.I.E.Liem@lumc.nl

**ABSTRACT**

**Introduction** Early diagnosis of systemic sclerosis (SSc) is important to start therapeutic interventions timely. Important risk factors for progression to SSc are the SSc-specific autoantibodies, of whom anti-centromere antibodies (ACA) and anti-topoisomerase I antibodies (ATA) are the most frequent. ATA is associated with a severe disease course. A more detailed characterisation of the ATA-response in SSc might increase insights in preclinical disease stages and improve prognostication. To address this we identified all patients with suspected very early ATA-positive SSc, defined as all patients who are ATA-positive not fulfilling American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) 2013 criteria, in the Leiden Combined Care in Systemic Sclerosis (CCISS)-cohort and found very low numbers.

**Methods** This triggered us to search the literature on the ATA prevalence in patients with suspected very early SSc and contribution of the SSc-specific autoantibodies to progression from suspected very early to definite SSc. To increase insights on the ATA-response in suspected very early SSc, we then evaluated the association between the ATA-response and time between onset of Raynaud's phenomenon (RP) and first non-RP symptom, as a proxy for progressing to definite SSc, in all patients with ATA-positive SSc from the Leiden CCISS-cohort.

**Results** In short, included studies show that prevalence of ATA is much lower in suspected very early SSc than in populations fulfilling ACR/EULAR 2013 criteria. After 1–15 years of follow-up, only 52% of the patients with suspected very early SSc progress to definite SSc. ATA-IgG levels tend to be higher in patients with ATA-positive SSc with more rapid disease progression.

**Conclusion** Although a role of ATA in disease progression is suggested, more studies on the ATA response in suspected very early SSc are warranted.

**INTRODUCTION**

Systemic sclerosis (SSc) is a rheumatic autoimmune disease with a pathogenesis involving a triad of autoimmunity, vasculopathy and fibrosis.<sup>1</sup> Early diagnosis of SSc is crucial to start therapeutic interventions before development

**WHAT IS ALREADY KNOWN ON THIS TOPIC**

- ⇒ Systemic sclerosis (SSc) specific autoantibodies are important risk factors for progression from suspected very early SSc to definite SSc.
- ⇒ More insight into the characterisation and prevalence of the SSc-specific autoantibodies during the development of SSc is necessary to improve disease prognostication.

**WHAT THIS STUDY ADDS**

- ⇒ Prevalence of anti-topoisomerase I antibodies (ATA) is much lower in suspected very early SSc than in populations fulfilling American College of Rheumatology/European Alliance of Associations for Rheumatology<sup>28</sup> 2013 criteria.
- ⇒ ATA-IgG levels tend to be higher in patients with ATA-positive SSc with less time between onset of Raynaud's phenomenon and first non-Raynaud's phenomenon symptom, as proxy for disease progression.

**HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY**

- ⇒ Although a role of ATA in disease progression is suggested, more detailed studies on the characterisation of ATA and underlying B-cell responses in suspected very early SSc are needed.
- ⇒ The low ATA prevalence among patients with suspected very early SSc suggests swift disease progression in ATA-positive SSc and consequently a different approach to identify this subgroup before development of irreversible organ damage.

or progression of organ damage. In 2013, the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria for SSc were published showing an increased sensitivity to classify patients with SSc early in the disease course.<sup>2</sup> In addition, criteria for suspected very early SSc were developed consisting of Raynaud's phenomenon (RP), SSc-specific autoantibodies, puffy fingers and abnormal nailfold

capillaroscopy.<sup>3,4</sup> Patients classified as suspected very early SSc do not fulfil ACR/EULAR 2013 criteria for SSc. The progression from suspected very early SSc to ACR/EULAR 2013 criteria is usually defined by the development of a first non-RP symptom.

Anti-topoisomerase I antibodies (ATA) and anti-centromere antibodies (ACA) are the most prevalent SSc-specific antinuclear autoantibodies,<sup>5</sup> and are used for disease and risk stratification.<sup>6,7</sup> In patients with suspected very early SSc, presence of SSc-specific autoantibodies are important predictors for the development of definite SSc.<sup>8,9</sup> However, so far little is known on the contribution of the SSc-specific autoantibodies to the underlying processes involved in disease progression and whether this is different between ATA and ACA. Given the importance of the SSc-specific autoantibodies for progression to SSc, more detailed characterisation of the autoantibody responses in preclinical disease stages might increase insights in disease development and contribute to improved disease prognostication. In this paper we show the different steps and analyses we undertook to evaluate the ATA characteristics during progression from suspected to definite SSc.

## THE CHALLENGE IN FINDING PATIENTS WITH SUSPECTED VERY EARLY SSc WITH ATA

For ACA, we recently studied 138 patients with suspected very early SSc and 487 patients with definite SSc with ACA and showed that ACA-IgG and ACA-IgM levels were significantly higher in patients with definite SSc.<sup>10</sup> In the patients with suspected very early SSc, progression to definite SSc was associated with higher ACA-IgG levels at baseline.<sup>10</sup> We set out to identify whether this observation also holds for ATA-positivity, but could only identify 4 patients with suspected very early ATA positive SSc in the 1077 patients referred to the Leiden Combined Care in Systemic Sclerosis (CCISS) cohort. The most recent study of the very early diagnosis of SSc (VEDOSS) project, a European multicentre study in suspected very early SSc, evaluated progression to SSc in 553 patients with suspected very early SSc.<sup>9</sup> Strikingly, although 32% of the patients with suspected very early SSc in this study were ACA-positive (=164), only 7% were ATA-positive (n=39). Intriguingly, the prevalence of ATA is much higher among patients with definite SSc: for example, 24% of the patients with SSc in the Leiden CCISS cohort is ATA-positive<sup>11</sup> and 39% in the European Scleroderma Trials and Research (EUSTAR) cohort.<sup>12</sup> These observations triggered us to perform a literature search to review the prevalence of ATA in patients with suspected very early SSc and on the contribution of the SSc-specific autoantibodies to progression from suspected very early to definite SSc.

## PART 1: LITERATURE STUDY

### Methods

The research question for the scoping literature review was 'What is the contribution of the SSc-specific autoantibodies and their underlying B cell response to the progression of suspected very early SSc to definite SSc?'

We searched PubMed with the following terms: 'very early SSc', 'VEDOSS', 'suspected', 'isolated RP', 'progression' and 'SSc'. All identified articles were assessed for relevant content by the corresponding author. Initial rejection for further evaluation was based on the information in the abstract; next, secondary rejection was based on the content of the full article. All other studies were included if they were original research in English, included greater than five patients and reported on prevalence of SSc-specific autoantibodies in suspected very early SSc, clinical characteristics of suspected very early SSc and/or the progression of isolated RP/suspected very early SSc to definite SSc.

### Results

We included the following studies: (1) six studies reporting on the prognostic value of SSc-specific autoantibodies for progression of RP or suspected very early SSc to definite SSc,<sup>8,9,13-17</sup> (2) six studies describing clinical characteristics of patients with suspected very early SSc<sup>18-23</sup> and (3) two studies investigating SSc-specific autoantibody responses in detail and their association with progression of RP or suspected very early SSc to definite SSc.<sup>10,24</sup>

The ATA prevalence reported in the studies on suspected very early SSc and VEDOSS ranges from 0.2% to 24% (tables 1 and 2). The lowest prevalence of ATA was reported in the studies that recruited patients based on RP. In studies also including patients with organ involvement, ATA prevalence was higher (tables 1 and 2). Progression from RP to definite SSc occurred in 0% to 21% of the patients, and progression from suspected very early SSc to definite SSc in 8% to 52% of the patients. Moinzadeh *et al* reported that patients with isolated RP with anti-RNA-polymerase III had 1.7 (SD: 6.4) years between RP and SSc onset, with ATA 3.6 (SD: 6.4) years and with ACA 10.8 (SD: 12.5) years.<sup>16</sup> In the other studies, no specific progression rates for the different autoantibody subgroups were reported. All studies except for the study of Trapiella-Martínez *et al* found that the presence of SSc-specific autoantibodies increased the risk for progression from RP or suspected very early SSc to definite SSc.<sup>15</sup> In the study of Trapiella-Martínez *et al*, patients who progressed from suspected very early SSc to definite SSc were ATA-positive more often than patients who did not progress (19% vs 8%).<sup>15</sup> Intriguingly, some studies describing clinical characteristics of patients with suspected very early SSc showed substantial prevalence of possible organ involvement, such as oesophageal symptoms, digital ulcers, puffy fingers in their populations, by which they might have fulfilled ACR/EULAR 2013 SSc criteria (table 2).

In order to elucidate if the SSc-specific autoantibodies are more than active bystanders in the development of SSc, it is important to study their response more in depth. So far, we found two studies evaluating the association between levels of autoantibodies and progression to definite SSc. The first study by Lande *et al* evaluated

**Table 1** Studies evaluating the association of the SSc-specific autoantibodies and the progression of RP/suspected very early SSc/VEDOSS to definite SSc

Author and year	Patients with suspected very early SSc		Patients with definite SSc		Results on progression from suspected very early SSc to definite SSc
	Definition	Total number	Definition	Total number of progressors	
Studies evaluating the prognostic value of the presence of SSc-specific autoantibodies on progression to definite SSc					
Bellando-Randone <i>et al</i> , 2021 <sup>9</sup>	RP, ANA positive, puffy fingers, SSc. Specific autoantibody positive, abnormal NC.	764/1150 patients of whom 553 had one follow-up visit available. Of N=553: <ul style="list-style-type: none"> <li>▶ 401 (73%) ANA.</li> <li>▶ 208 (38%) SSc-Ab.</li> <li>▶ 164 (30%) ACA.</li> <li>▶ 39 (7%) ATA.</li> <li>▶ 6 (1%) ARA.</li> </ul>	Fulfilling ACR/EULAR 2013 criteria.	133 of 254 with 5 years follow-up available.	126/133 (95%) were ANA-positive. Seventy per cent of the patients with SSc-specific autoantibodies reached the endpoint, which translates to a risk ratio of 5.03 (2.93; 8.66) in univariable logistic regression. Adjusted for the other VEDOSS criteria, the risk ratio of the SSc-specific autoantibodies was 4.20 (2.21; 7.99). The results of the Cox regression models, incorporating the fully available follow-up data, are in line with this.
Riccardi <i>et al</i> , 2020 <sup>13,14</sup>	RP and either presence of SSc autoantibodies or NC or both.	N=102 <ul style="list-style-type: none"> <li>▶ 72 (71%) ANA.</li> <li>▶ 46 (45%) ACA.</li> <li>▶ 16 (15%) ATA.</li> <li>▶ 2 anti-Tho, 1 anti PM Scl.</li> </ul>	Fulfilling ACR/EULAR 2013 criteria.	46/102 (45%) in median disease duration of 3 years. <sup>1,12</sup>	HR's for progression to definite SSc: <ul style="list-style-type: none"> <li>▶ ATA: 11.57.</li> <li>▶ ANA: 6.93.</li> <li>▶ Avascular areas on NC: 5.03.</li> <li>▶ ACA: 3.92.</li> </ul>
Trapiella-Martinez <i>et al</i> , 2017 <sup>15</sup>	=RP with SSc Ab, ANA positivity or NC. Divided into two groups: <ol style="list-style-type: none"> <li>1. Very early SSc: RP, NC, SSc Ab.</li> <li>2. Early SSc: +reflux/decreased DLCO without ILD/PAH or diastolic dysfunction or DU/PS/TE/calculinosis/arthritis.</li> </ol>	Of 1632 patients in RESCLE cohort: 36/1632 (2.2%) very early SSc. <ul style="list-style-type: none"> <li>▶ 36 (100%) ANA.</li> <li>▶ 19 (53%) ACA.</li> <li>▶ 2 (6%) ATA.</li> <li>▶ 0 ARA.</li> </ul> 111/1632 (6.8%) early SSc. <ul style="list-style-type: none"> <li>▶ 101 (91%) ANA.</li> <li>▶ 50 (50%) ACA.</li> <li>▶ 12 (12%) ATA.</li> <li>▶ 0 ARA.</li> </ul>	Unclear in the article.	3/36 (8%) very early SSc, of whom two fulfilled. ACR/EULAR 2013 criteria. 31/111 (28%) patients with early SSc, of whom 20 fulfilled. ACR/EULAR 2013 criteria.	Six per cent of the very early patients already fulfilled ACR/EULAR 2013 criteria and 24% of the patients with early SSc. The early subset has a higher risk of progression to definite SSc than the very early subset (OR 4.26 (95% CI: 1.22 to 14.92)). Digestive involvement was an independent risk factor of progression (OR 17; 95% CI, 6.1 to 47.2). Progressors had ATA more often than non-progressors (19% vs 8%, p=0.113).
Moinzadeh <i>et al</i> , 2012 <sup>16</sup>	Isolated RP.	N=569 <ul style="list-style-type: none"> <li>▶ 7% ANA.</li> <li>▶ 1% ACA.</li> <li>▶ &lt;0.2% ATA.</li> </ul>	Clinical features of SSc.	N=8 (1.5%).	7/8 had an SSc pattern on NC as well as positive ANA's at first presentation. Progression to a connective tissue disease was not observed in any patient with negative autoimmune serology on more than one visit and normal capillaroscopy score.
Ingegnoli <i>et al</i> , 2010 <sup>17</sup>	Isolated RP.	N=288 <ul style="list-style-type: none"> <li>▶ 128 (45%) ANA.</li> <li>▶ 44 (15%) ACA.</li> <li>▶ 12 (4%) ATA.</li> </ul>	First non-Raynaud clinical feature of SSc.	N=34 (12%).	The 5-year incidence for SSc was 21% (95% CI: 10% to 32%). Other CTDs developed in 42 patients (11 cases of RA, 25 cases of UCTD, 3 cases of SLE, 2 cases of dermatomyositis and 1 case of MCTD). The 5-year incidence for all events was 45.8% (95% CI: 31% to 61%) and. Isolated ANA positivity increased the hazard of an event with a sub-distribution HR of 9.70), then if a patient was also ACA the sub-distribution HR increased with 3.93. ATA positivity did not indicate a further increase in the hazard of SSc (sub-distribution HR 1.37).
Koenig <i>et al</i> , 2008 <sup>8</sup>	Primary RP: no abnormalities Pre-CTD: +puffy fingers, Ab but not SSc-specific Ab. Early SSc: +SSc specific Ab, SSc NC without displaying clinical manifestations of SSc or another CTD.	Primary RP: N=299 Pre-CTD: N=317 Early SSc: N=168 <ul style="list-style-type: none"> <li>▶ 88/168 (52%) abnormal NC.</li> <li>▶ 80/168 (48%) SSc Ab.</li> <li>▶ 34/168 (20%) ACA.</li> <li>▶ 14/168 (8%) ATA.</li> <li>▶ 25/168 (15%) ARA.</li> <li>▶ 12/168 (7%) Th/To.</li> </ul>	Fulfilling ACR 1980 criteria.	Primary RP: N=0. Pre-CTD: n=8 (3%). Early SSc: n=66 (47%).	71 of the 74 patients (96%) who progressed to definite SSc were ANA-positive. SSc autoantibodies were present in 78.4% of the patients (58 of 74): anti-CENP-B (n=33 (44.6%)) and anti-Th (n=13 (17.6%)) were the most frequent, whereas anti-topo I (n=6 (8.1%)) and anti-RNAP III (n=9 (12.2%)) were the least frequent. The strongest independent predictors of definite SSc were positive ANAs (adjusted HR 5.67), SSc autoantibodies (HR 4.7) and an SSc pattern on NC (HR 4.5).

Continued

Table 1 Continued

Author and year	Patients with suspected very early SSc		Patients with definite SSc		Results on progression from suspected very early SSc to definite SSc
	Definition	Total number	Definition	Total number of progressors	
Studies evaluating the prognostic value of the levels of SSc-specific autoantibodies on progression to definite SSc					
Van Leeuwen <i>et al</i> , 2021 <sup>10</sup>	ACA-IgG positivity and RP+puffy fingers or nailfold capillaroscopy abnormalities.	N=138 ▶ 138/138 (100%) ACA.	Fulfilling ACR/EULAR 2013 SSc criteria.	N=48.	48 patients with very early ACA-positive SSc progressed to definite SSc within 5 years. Progressors were older, had longer follow-up duration and shorter RP duration (2 (1; 5) vs 5 (3; 7), p=0.69) compared with non-progressors. Progression to definite SSc was associated with higher IgG ACA levels at baseline (OR 4.3 (95% CI 1.7 to 10.7) in a logistic regression adjusted for age and disease duration since the first RP symptom.
Lande <i>et al</i> , 2021 <sup>24</sup>	RP and ATA or ACA.	VEDOSS discovery cohort: n=31 ▶ 64% ACA. ▶ 23% ATA. VEDOSS replication cohort: n=48 ▶ 61% ACA. ▶ 5% ATA.	Fulfilling ACR/EULAR 2013 SSc criteria.	N=42. ▶ 5% ACA. ▶ 71% ATA.	17/31 patients in the VEDOSS discovery cohort and 15/48 patients in the VEDOSS replication cohort progressed to definite SSc. SSc progressors showed a similar anti-CXCL4/CXCL4-L1 autoantibody response to SSc non-progressors.

Ab, autoantibodies; ACA, anti-centromere antibodies; ACR, American College of Rheumatology; ANA, anti-nuclear antibodies; ARA, anti-RNA polymerase III antibodies; ATA, anti-topoisomerase I antibodies; CTD, connective tissue disease; DLCO, diffusing lung capacity for carbon monoxide; DU, digital ulcer; EULAR, European Alliance of Associations for Rheumatology; ILD, interstitial lung disease; MCTD, mixed connective tissue disease; NC, nailfold capillaroscopy; PAH, pulmonary arterial hypertension; PS, pitting scars; RESCLE, Spanish Scleroderma Registry Cohort; RP, Raynaud's phenomenon; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; TE, teleangiectasia; UCTD, undifferentiated connective tissue disease; VEDOSS, very early diagnosis of SSc.

anti-CXCL4 and found no differences in anti-CXCL4 levels between patients who progressed to definite SSc and patients who did not.<sup>24</sup> The second study of our own research group (van Leeuwen *et al*<sup>10</sup>) evaluated ACA isotype levels. Of all patients with suspected very early SSc with follow-up (n=115), 39% progressed to definite SSc and the ACA-IgG levels at baseline were significantly associated with progression to definite SSc.<sup>10</sup>

## PART 2: TIME BETWEEN RP AND FIRST NON-RP

The results of the literature review suggest that ATA positivity is associated with a more rapid progression of disease towards fulfilment of the ACR/EULAR 2013 SSc criteria, based on the strikingly low prevalence of ATA among suspected very early SSc.<sup>25</sup> The mechanism behind this is unknown. To complement these observations, we aimed to investigate if the ATA response is associated with the (rate of) disease progression in suspected very early SSc. To tackle the problem of low numbers of patients with suspected very early SSc with ATA, we evaluated time between onset of RP and first non-RP symptom as a proxy for progressing to definite SSc, and investigated if this is associated with clinical and ATA response characteristics. We hypothesise that RP may be the first manifestation in suspected very early SSc. We assumed that a shorter time between RP and first non-RP symptoms reflects more rapid disease progression and thus (risk for) more severe disease. For this part, we took advantage of the prospective Leiden CCISS cohort.<sup>26</sup>

## Methods

### Patients

Patients with SSc, fulfilling the ACR/EULAR 2013 SSc criteria at cohort entry<sup>2</sup> and positive for ATA-IgG, were included from the prospective CCISS cohort at Leiden University Medical Center until 1 January 2022.<sup>26</sup> We used the following definitions for the included patients:

- ▶ Definite SSc: fulfilling ACR/EULAR 2013 criteria.<sup>2</sup> Early SSc refers to patients with definite SSc with a short disease duration (<2 years since first non-RP).
- ▶ Suspected very early SSc: fulfilling VEDOSS criteria, but not the ACR/EULAR 2013 criteria.<sup>3, 4</sup> The VEDOSS criteria consist of RP, SSc-specific autoantibodies, puffy fingers and abnormal nailfold capillaroscopy.

All patients with SSc in the CCISS cohort undergo annual screening for organ involvement and gave informed consent.

### Disease characteristics

At baseline visit, clinical data and blood samples were collected from all patients. A detailed explanation of the definitions for organ involvements are shown in the online supplemental file 1. Baseline was defined as the first visit in the CCISS cohort. Patients were categorised in three groups using the terciles of time between RP and first non-RP: (1) ≤3 months, (2) 4 to ≤24 months (3) ≥25 months.

**Table 2** Prevalence of SSc-specific autoantibodies and clinical characteristics in patients with suspected very early SSc

Author and year	Definition	Total number	Clinical characteristics
Hernández <i>et al</i> , 2021 <sup>23</sup>	Patients not fulfilling any of the classification criteria, but with evidence for SSc based on the VEDOSS criteria.	N=101 ▶ 93% ANA. ▶ 43% ACA. ▶ 4% ATA. ▶ 7% ARA.	Mean age at onset of first RP symptom: 40 years (SD: 17), whereas patients fulfilling ACR/EULAR 2013 criteria had a mean age of 47 years (SD: 18) and patients fulfilling ACR 1980 criteria 47 years (SD: 17).
Blaja <i>et al</i> , 2021 <sup>22</sup>	Clinical expert diagnosis of RP, and additional SSc features (puffy fingers, SSc autoantibodies, NC) but without fulfilling ACR/EULAR 2013 criteria.	N=102 ▶ 96% ANA. ▶ 48% ACA. ▶ 1% ATA. ▶ 5% ARA.	Median disease duration was 4.1 years (IQR 1.6–11.5). 52/96 (54%) had a disease duration of <5 years, and 28/96 (29%) patients had a disease duration of >10 years. Clinical characteristics of patients <5 years disease duration were similar to patients >5 years, but there were trends between <5 and >5 years, respectively: ▶ Puffy fingers: 23% vs 14%. ▶ Oesophageal symptoms: 24% vs 36%. ▶ Abnormal NC: 19% vs 14%.
Bruni <i>et al</i> , 2015 <sup>20</sup>	Presence of RP, puffy fingers, ANA, plus NC abnormalities and/or disease-specific antibodies.	N=110 ▶ 59/110 (54%) ACA. ▶ 21/110 (19%) ATA.	Four patients reported a history of digital pitting scars, while 25 patients presented an active DU or reported a history of DUs. Sixteen patients presented with active DUs (14/16 also reporting a history of previous DUs), while the other nine patients reported a history of DUs only.
Lepri <i>et al</i> , 2015 <sup>21</sup>	VEDOSS criteria.	N=55 with oesophageal manometry ▶ 55/55 (100%) ANA. ▶ 24/55 (44%) ACA. ▶ 11/55 (24%) ATA. N=42 with anorectal manometry ▶ 2/42 (100%) ANA. ▶ 21/42 (50%) ACA. ▶ 10/42 (24%) ATA.	In majority of patients oesophageal and anal involvement in present. Oesophageal manometry group: ▶ 25/51 (49%) had DLCO <80%. ▶ 22/45 (49%) had lung involvement on HRCT. Anorectal manometry: ▶ 21/42 (50%) had DLCO <80%. ▶ 18/35 (51%) had lung involvement on HRCT.
Minier <i>et al</i> , 2014 <sup>19</sup>	RP.	N=469 ▶ 318 (68%) ANA. ▶ 135 (67%) ACA. ▶ 35 (7%) ATA. ▶ 2 (0,4%) ARA.	An NC SSc pattern was detected in 13.4% of patients with ANA–RP. In patients who are ANA-positive, oesophageal symptoms was reported in 38%, previous or current puffy fingers in 35%, telangiectasia in 12%, sclerodactyly in 11%, digital ulcers in 6% and pitting scars in 5%.
Valentini <i>et al</i> , 2011 <sup>18</sup>	Early SSc: RP, SSc-autoantibodies and/or SSc NC. Probable SSc: + DU/scars, puffy fingers, arthritis, telangiectasia, dysphagia/heartburn, shortness of breath.	Early SSc: n=19. Probable SSc: n=51. In total: 13 ATA, 47 ACA (not specified per patient group).	An inverted mitral E: A ratio and/or a diffusing lung capacity for CO <80% and/or basal low oesophageal sphincter pressure <15 mm Hg were detected in 37/51 patients with probable SSc (72%) and 8/19 patients with early SSc (42%). Presence of autoantibody increased the risk of organ involvement with 4.35 (95% CI: 1.96 to 9.67).

ACA, anti-centromere antibodies; ACR, American College of Rheumatology; ANA, anti-nuclear antibodies; ARA, anti-RNA polymerase III antibodies; ATA, anti-topoisomerase I antibodies; DLCO, diffusing lung capacity for carbon monoxide; DU, digital ulcer; EULAR, European Alliance of Associations for Rheumatology; HRCT, high-resolution CT; NC, nailfold capillaroscopy; RP, Raynaud's phenomenon; SSc, systemic sclerosis; VEDOSS, very early diagnosis of SSc.

### Anti-topoisomerase I assay and measurements

One hundred and one patients with ATA-positive SSc were randomly selected for ATA measurements. A detailed description of the ATA assay is described elsewhere.<sup>27</sup>

### Statistical analysis


Disease characteristics at baseline were compared using independent t-tests, Kruskal-Wallis, Mann-Whitney U and  $\chi^2$  tests between the three times between the patients with RP and first non-RP groups. Correlation between time between RP and first non-RP symptom and the ATA isotype levels was assessed using Spearman's rank order

correlation test. Based on figure 1, a cut-off of 1000 IE was taken and time between RP and first non-RP was compared between patients with high ATA-IgG levels ( $\geq 1000$  AU/mL) and lower ATA-IgG levels (<1000 AU/mL) using Kruskal-Wallis tests. Analyses were conducted with SPSS V.25.0 (SPSS, Chicago, Illinois, USA). A p value of <0.05 was considered statistically significant.

## RESULTS

### Clinical characteristics

In total, 169 patients were ATA-IgG-positive. Of the 708 patients with definite SSc fulfilling ACR/EULAR 2013



**Figure 1** Anti-topoisomerase I antibody (ATA) IgG, IgA and IgM levels in 101 patients with ATA-IgG+SSc at baseline. Spearman's correlation for IgG:  $-0.202$  ( $p=0.041$ ); for IgA,  $-0.075$  (not significant) and IgM,  $0.027$  (not significant). RP, Raynaud's phenomenon; SSc, systemic sclerosis.

SSc criteria, 163 (23%) were ATA-positive. Of the 115 suspected very early patients, 4 (3%) were ATA-positive. Given the low number of ATA-positive suspected very early SSc, we focused on the 163 patients with SSc for evaluation of clinical characteristics and antibody response. However, in 2/163 patients with ATA-positive SSc, dates of RP or first non-RP symptom was unknown and these patients were therefore excluded. For this part, we thus included 161 patients with ATA-positive SSc. Of these included patients, 55 (34%) had a time between RP and the first non-RP symptom of  $\leq 3$  months, 54 (34%) between 4 and  $\leq 24$  months and 52 (32%) between  $\geq 25$  months.

At baseline visit, patients with  $\leq 3$  months between RP and first non-RP were men more often compared with patients with 4 to  $\leq 24$  months and  $\geq 25$  months (47% vs 26% vs 31%, respectively,  $p=0.035$ ), had a higher skin

score (9 (5; 17) vs 5 (2; 14) vs 4 (2; 7), respectively,  $p=0.002$ ) and had diffuse cutaneous SSc more often (53% vs 52% vs 23%, respectively,  $p=0.004$ ; (table 3)).

The prevalence of interstitial lung disease (ILD) on high-resolution CT (HRCT) at baseline visit was similar between all groups (64% vs 63% vs 64%,  $p=0.690$ ), whereas the proportion of patients with ILD on HRCT and an abnormal pulmonary function test was higher in the group of  $\leq 3$  months and 4 to  $\leq 24$  months compared with  $\geq 25$  months (31% vs 28% vs 15%, respectively,  $p=0.158$ ; Table 3).

Skin tightening was the first non-RP symptom most frequently reported, namely in 78 (48%) patients with ATA-positive SSc, followed by sclerodactyly/puffy fingers in 28 (17%). In the patients with  $\leq 3$  months between RP and first non-RP, sclerodactyly/puffy fingers was more frequently reported (12 (28%)) compared with patients

**Table 3** Baseline characteristics of patients with included anti-topoisomerase I antibodies positive SSc categorised in groups based on time between RP and non-RP

	Total: n=161	$\leq 3$ months n=55	4 to $\leq 24$ months n=54	$\geq 25$ months n=52	P value
Age, mean (SD)	52 (15)	53 (15)	52 (13)	51 (16)	0.848
Female, n (%)	106 (65)	29 (53)	40 (74)	36 (69)	0.035
Years follow-up, median (min; max)	3 (0; 11)	3 (0; 11)	5 (0; 11)	3 (0; 10)	0.105
Modified Rodnan Skin Score, median (IQR)	6 (2–12)	9 (5–17)	5 (2–14)	4 (2–7)	0.002
Limited cutaneous SSc, n (%)	79 (48)	22 (40)	19 (35)	36 (69)	0.004
Diffuse cutaneous SSc, n (%)	70 (43)	29 (53)	28 (52)	12 (23)	
Digital ulcers, n (%)	21 (13)	8 (15)	7 (13)	6 (12)	0.879
ILD on HRCT, n (%)	103 (63)	35 (64)	19 (35)	33 (64)	0.690
ILD combined, n (%)	41 (25)	17 (31)	15 (28)	8 (15)	0.158
First non-RP symptoms, n (%)					0.090
▶ Skin tightening	78 (48)	23 (49)	35 (66)	20 (44)	
▶ Sclerodactyly or puffy fingers	28 (17)	12 (28)	5 (9)	9 (20)	
▶ Fingertip lesions	17 (10)	5 (11)	4 (8)	8 (17)	
▶ Telangiectasia	4 (3)	–	3 (6)	1 (2)	
▶ ILD	17 (10)	6 (13)	3 (6)	7 (15)	
▶ Pulmonary arterial hypertension	–	–	–	–	
▶ Myositis	2 (1)	–	1 (2)	1 (2)	
▶ Abnormal nailfold capillaries	2 (1)	–	2 (4)	–	

HRCT, high-resolution CT; ILD, interstitial lung disease; N, number; RP, Raynaud's Phenomenon; SSc, systemic sclerosis.

**Table 4** ATA characteristics of patients with included ATA-positive SSc categorised in groups based on time between RP and non-RP

	Total: n=101	*≤3 months n=32	*4 to ≤24 months n=34	*≥25 months n=35	P value
ATA-IgG levels (aU/mL), median (IQR)	454 (171–854)	551 (253–1145)	508 (228–1056)	289 (164–780)	0.361
ATA-IgA levels (aU/mL), median (IQR)	2743 (959–7700)	2655 (924–8637)	3037 (1117–10071)	2072 (852–6086)	0.536
ATA-IgM levels (aU/mL), median (IQR)	771 (283–2084)	597 (251–2169)	879 (339–2042)	829 (278–1401)	0.904
ATA-IgG positivity, n (%)	101 (100)	32 (100)	34 (100)	35 (100)	–
ATA-IgA positivity, n (%)	100 (99)	32 (100)	33 (97)	35 (100)	0.370
ATA-IgM positivity, n (%)	64 (64)	19 (59)	23 (68)	22 (65)	0.779

\*Time between onset of Raynaud's phenomenon (RP) and first non-RP symptom.  
ATA, anti-topoisomerase I antibodies ; N, number; SSc, systemic sclerosis.

with 4 to ≤24 months (5 (9%)) and ≥25 months (9 (20%); Table 3).

### ATA-IgG, ATA-IgM and ATA-IgA levels

Serum samples obtained at baseline (inclusion in the cohort) were analysed in 101/161 patients with ATA-positive SSc. Presence of ATA-IgA and ATA-IgM was similar between the three groups (table 4). A clear decrease in ATA-IgG levels was seen between the groups categorised on time between RP and first non-RP symptoms ( $p=0.361$ ; figure 2/table 4). ATA-IgG levels correlated weakly with the time between RP and first non-RP (Spearman's rho:  $-0.202$ ,  $p=0.041$ ; Figure 1), but ATA-IgM and ATA-IgA levels did not. In patients with ATA-IgG levels ≥1000 AU/mL median time to develop a first non-RP symptom was 7 months (range 0–24) as compared with 12 months in patients with ATA-IgG levels <1000 AU/mL (range: 1–65;  $p=0.089$ ).


### DISCUSSION

Our literature search shows that the progression rate of suspected very early SSc to definite SSc varies between 8% and 52%. Among patients with suspected very early

SSc the lowest prevalence of ATA is observed in patients recruited based on RP and highest in patients with suspected very early SSc with organ involvement. In addition, in patients with definite SSc from the Leiden CCISS cohort, ATA-IgG levels were higher in patients with shorter duration between first RP and first non-RP symptom. We observed that patients with ATA-IgG-positive SSc with a shorter time between RP and non-RP had severe skin involvement more often, but other disease complications were comparable between groups.

### Suspected very early SSc: characteristics, role of SSc-specific autoantibodies and terminology

The relevance of SSc-specific autoantibodies, including ATA, as predictors for development of SSc has been confirmed by multiple studies.<sup>8,9</sup> The ACR/EULAR SSc criteria in 2013 have led to the identification of more patients with ATA-positive SSc with a less severe disease course,<sup>28</sup> which is an important step towards early recognition of the disease. Like in the VEDOSS study,<sup>9</sup> also in the Leiden CCISS cohort the prevalence of ATA among patients with the very early SSc was lower than expected based on the distribution in definite SSc. From the



**Figure 2** Baseline anti-topoisomerase I antibody (ATA) IgG, IgA and IgM levels in 101 patients with ATA-IgG+SSc, categorised in groups based on time between RP and first non-RP symptom. Patients are categorised in three groups based on the terciles of the time between RP and first non-RP symptom: (1) ≤3 months (n=55), (2) 4 to ≤24 months (n=54) and (3) ≥25 months (n=52). The ATA-IgG, ATA-IgA and ATA-IgM levels were not statistically significant difference between the groups. RP, Raynaud's phenomenon; SSc, systemic sclerosis.

literature review it becomes apparent that the prevalence of ATA in patients with suspected very early SSc ranges from 0.2% to 24%, which is a rather wide range. As the majority of studies have been performed in Europe, it is not likely that ethnicity plays a role. Also, the percentage of men in the studies was generally the same and ranged from 8% to 11%. Therefore, we think that the definitions of suspected very early SSc used in the included studies explain the observed difference, because the percentage of ATA positivity is lowest in studies that only include RP and highest in studies that also include patients with organ involvement. Indeed this might again underline that in ATA-positive disease, progression to full blown disease is swift, decreasing the chance of an ATA-positive patient to be captured in the RP only phase.

The terminology of the classification of the different stages in SSc is complex and might interfere with uniform patient stratification. First, patients with all signs or symptoms of the VEDOSS criteria already fulfil the 2013 ACR/EULAR SSc classification criteria. This can be confusing and blur clinical association studies to improve phenotyping in SSc. Second, the current terminology VEDOSS (very early diagnosis of SSc) could be questioned as well. As shown in [table 1](#), of all patients fulfilling these criteria up to 50% will eventually progress to a diagnosis. Therefore, 'clinical suspicion' is perhaps more appropriate to classify these patients.

To proceed in this field we propose to perhaps take advantage of the development in other autoimmune diseases like rheumatoid arthritis (RA). In RA, the concept of clinically suspect arthralgia has been developed to facilitate clinical studies in preclinical stages.<sup>29</sup> In contrast to RA, where this is mainly based on clinical features, in patients with RP, presence of autoantibodies and abnormal nailfold capillaries, next to puffy fingers, are main risk factors.<sup>9 19</sup> This indicates that additional investigations are needed to identify patients at risk. To increase insights in the development of SSc, it is thus necessary to identify patients in preclinical stages, that is, persons who do not have a diagnosis yet. As the presence of autoantibodies is a profound risk factor, we propose to make this distinction based on the presence of RP and anti-nuclear antibody (ANA) positivity/SSc-specific autoantibody.

### Time between RP and non-RP

To deal with the low number of patients with suspected very early ATA-positive SSc, we took time between RP and first non-RP symptom as a proxy for progression to SSc. Of course, these are not one-to-one applicable but could provide a direction. We observed an association with time between RP and first non-RP symptom and higher ATA-IgG, but not for ATA-IgM or ATA-IgA. This is in line with research in ACA-positive SSc, which shows that progression from suspected very early ACA-positive SSc to definite SSc was associated with higher ACA-IgG levels at baseline.<sup>10</sup> While we confirmed the previous observed association between ATA-IgG level and lung

progression,<sup>15</sup> we did not see an association between ATA-IgM and time between first RP and first non-RP.<sup>27</sup> The reason for a lack of association between ATA-IgM and time between RP and non-RP in our cohort might be the fact that we studied patients who already progressed to definite SSc. While the previous study evaluated disease progression yes/no 1 year after sample collection,<sup>27</sup> the current study evaluated association between presence of ATA-IgM and the time between RP and first non-RP, which was preceding sample collection.

Currently, testing for the different isotypes of ATA in serum is not part of the routine clinical diagnostic workup and also not commonly available as standardised test in diagnostic laboratories. Recent research shows that the presence of autoreactive IgM is associated with disease progression in both ACA and ATA-positive SSc.<sup>10 27</sup> IgM has the shortest serum half-life (7 days) compared with IgG and IgA and can therefore be considered a proxy for the recent and/or continuous stimulation of the adaptive immune response. The observed association between the presence of ATA-IgM with SSc disease progression in the near future<sup>27</sup> points to a close association between (activation of) the ATA B-cell response and disease progression and suggests that ATA-expressing B cells may contribute to disease progression. Antibodies of the IgA isotype are generally associated with immune responses at mucosal surfaces. It is intriguing to speculate how these might associate with antigen expression in the pulmonary and/or gastrointestinal environment. We hypothesise that more insight into the evolution of the different ATA isotypes will increase insights in how autoreactive B cells contribute to disease progression in SSc. As the observations described are still experimental in nature, however, testing different ATA isotypes in serum cannot yet be advocated for routine clinical care. Nonetheless, we consider that testing for the presence of ATA-IgM might be of additive value to guide treatment decisions in SSc in the future.

Identifying patients with suspected very early SSc with ATA remains challenging, and we were thus not able to prospectively evaluate the association between ATA levels and progression from very early SSc to definite SSc. The observation that higher ATA-IgG is associated with shorter time between first RP and first non-RP might indicate a pathogenic role of the ATA B-cell response in the pathophysiology of SSc, a research topic which has intrigued researchers for many years. Recently, Senécal *et al*<sup>30</sup> updated criteria, originally proposed by Naparstek and Plotz,<sup>31</sup> for the definition of pathogenic autoantibodies in SSc. They concluded that ATA has the most evidence in favour of a possible pathogenic role compared with the other SSc-specific autoantibodies as ATA had evidence for all criteria except for the seventh criterion.<sup>30</sup> The seventh criterion states that the autoantibody should be found along with a plausible target antigen at the site of the tissue damage. This is difficult to demonstrate in a chronic disease, and underlines the importance to identify ATA-positive individuals before



progression to definite SSc to enable evaluation in early stages without chronic organ damage.

Regarding the second aim of this paper, we found that patients with a shorter disease duration were men and had skin involvement more often, which is in line with previous research<sup>16 32</sup> and clinical experience. Interestingly, the prevalence of ILD on HRCT in the three patient groups based on time between RP and non-RP in this study was similar, but a trend towards a lower prevalence of clinically meaningful ILD in the group with the longest time between RP and non-RP was observed. This is an intriguing observation which we do not yet fully comprehend. As ILD is currently the most prominent cause of death in patients with SSc,<sup>33</sup> this warrants further research.

Limitations of this study include the small number of patients and the possible recall bias of the onset of RP and non-RP by patients. Duration since first Raynaud is evaluated at baseline in all patients following a standardised intake questionnaire. The same method is applied to all patients and therefore it is unlikely that recall bias is different between the three groups. For this reason, we conclude that the observed association between ATA-IgG and more rapid progression is likely valid. Another limitation is that we do not know whether ATA have been present before onset of RP; as a consequence the interval between expression of ATA and development of first SSc-related symptom is not known. On the other hand, the fact that the proportion of clinically meaningful ILD is comparable between the three groups indicates that—if existing—the incident ATA-positive cases are equally distributed among the groups. However, our results do indicate a possible pathogenic role of ATA and warrant further multicentre research on the progression of patients with very early ATA to definite SSc.

To conclude, prevalence of ATA is much lower in suspected very early SSc than in populations fulfilling ACR/EULAR 2013 criteria. ATA-IgG levels tend to be higher in patients with ATA-positive SSc with more rapid disease progression. Although a role of ATA in disease progression is hereby suggested more detailed studies in preclinical SSc are warranted. To achieve sufficient power joint effort between expert clinics to identify persons with RP and ATA is necessary.

**Contributors** Concept and design: SIEL and JDV-B. Acquisition of data: SIEL and BAW. Analysis and interpretation: SIEL, SN, CMF, REMT, CFA, TWJH, HUS and JDV-B. Drafting the manuscript: SIEL and JDV-B. Revising the manuscript critically: All authors. All authors read and approved the final manuscript. SIEL and JDV-B accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Consent obtained directly from patient(s).

**Ethics approval** This study involves human participants and was approved by METC-LDD (REU 043/SH/sh and CME no. B16.037). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Sophie I E Liem <http://orcid.org/0000-0003-0328-7062>

Sam Neppelenbroek <http://orcid.org/0000-0002-9582-2837>

René E M Toes <http://orcid.org/0000-0002-9618-6414>

Tom W J Huizinga <http://orcid.org/0000-0001-7033-7520>

Hans Ulrich Scherer <http://orcid.org/0000-0002-5700-5617>

#### REFERENCES

- Denton CP, Khanna D. Systemic sclerosis. *Lancet* 2017;390:1685–99.
- van den Hoogen F, Khanna D, Fransen J, *et al*. 2013 classification criteria for systemic sclerosis: an American College of rheumatology/european League against rheumatism collaborative initiative. *Ann Rheum Dis* 2013;72:1747–55.
- Avouac J, Fransen J, Walker UA, *et al*. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a delphi consensus study from EULAR scleroderma trials and research group. *Ann Rheum Dis* 2011;70:476–81.
- Matucci-Cerinic M, Allanore Y, Czirják L, *et al*. The challenge of early systemic sclerosis for the EULAR scleroderma trial and research Group (EUSTAR) community. it is time to cut the Gordian knot and develop a prevention or rescue strategy. *Ann Rheum Dis* 2009;68:1377–80.
- Allanore Y, Simms R, Distler O, *et al*. Systemic sclerosis. *Nat Rev Dis Primers* 2015;1:15002.
- Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. *Nat Rev Rheumatol* 2010;6:112–6.
- Walker UA, Tyndall A, Czirják L, *et al*. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research Group database. *Ann Rheum Dis* 2007;66:754–63.
- Koenig M, Joyal F, Fritzler MJ, *et al*. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. *Arthritis Rheum* 2008;58:3902–12.
- Bellando-Randone S, Del Galdo F, Lepri G, *et al*. Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European scleroderma trial and research Group multicentre, longitudinal registry study for very early diagnosis of systemic sclerosis (VEDOSS). *The Lancet Rheumatology* 2021;3:e834–43.
- van Leeuwen NM, Boonstra M, Bakker JA, *et al*. Anticentromere antibody levels and isotypes and the development of systemic sclerosis. *Arthritis Rheumatol* 2021;73:2338–47.
- Markus IM, Meijs J, de Boer B, *et al*. Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies. *Rheumatology (Oxford)* 2017;56:1081–8.
- Sobanski V, Giovannelli J, Allanore Y, *et al*. Phenotypes determined by cluster analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis. *Arthritis Rheumatol* 2019;71:1553–70.
- Riccardi A, Marcoccia A, Borgia A, *et al*. Undifferentiated connective tissue disease at risk of systemic sclerosis: a weighted score to identify patients who will evolve. *Autoimmun Rev* 2019;18:102358.
- Riccardi A, Marcoccia A, Valentini G. The challenge of very early systemic sclerosis. *J Rheumatol* 2020;47:1724.

- 15 Trapiella-Martínez L, Díaz-López JB, Caminal-Montero L, *et al*. Very early and early systemic sclerosis in the spanish scleroderma registry (RESACLE) cohort. *Autoimmun Rev* 2017;16:796–802.
- 16 Moinzadeh P, Nihtyanova SI, Howell K, *et al*. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. *Clin Rev Allergy Immunol* 2012;43:249–55.
- 17 Ingegnoli F, Boracchi P, Gualtierotti R, *et al*. Improving outcome prediction of systemic sclerosis from isolated raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy. *Rheumatology (Oxford)* 2010;49:797–805.
- 18 Valentini G, Cuomo G, Abignano G, *et al*. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. *Rheumatology (Oxford)* 2011;50:317–23.
- 19 Minier T, Guiducci S, Bellando-Randone S, *et al*. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. *Ann Rheum Dis* 2014;73:2087–93.
- 20 Bruni C, Guiducci S, Bellando-Randone S, *et al*. Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. *Rheumatology (Oxford)* 2015;54:72–6.
- 21 Lepri G, Guiducci S, Bellando-Randone S, *et al*. Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. *Ann Rheum Dis* 2015;74:124–8.
- 22 Blaja E, Jordan S, Mihai C-M, *et al*. The challenge of very early systemic sclerosis: a combination of mild and early disease? *J Rheumatol* 2021;48:82–6.
- 23 Hernández J, Jordan S, Dobrota R, *et al*. The burden of systemic sclerosis in switzerland-the swiss systemic sclerosis EUSTAR cohort. *Swiss Med Wkly* 2021;151:w20528.
- 24 Lande R, Palazzo R, Mennella A, *et al*. New autoantibody specificities in systemic sclerosis and very early systemic sclerosis. *Antibodies (Basel)* 2021;10:12.
- 25 Wirz EG, Jaeger VK, Allanore Y, *et al*. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. *Ann Rheum Dis* 2016;75:1285–92.
- 26 Meijs J, Schouffoer AA, Ajmone Marsan N, *et al*. Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis. *RMD Open* 2016;2:e000159.
- 27 Boonstra M, Bakker JA, Grummels A, *et al*. Association of anti-topoisomerase I antibodies of the IgM isotype with disease progression in anti-topoisomerase I-positive systemic sclerosis. *Arthritis Rheumatol* 2020;72:1897–904.
- 28 Boonstra M, Ninaber MK, Ajmone Marsan N, *et al*. Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria. *Rheumatology (Oxford)* 2019;58:730–2.
- 29 van Steenberg HW, Aletaha D, Beart-van de Voorde LJJ, *et al*. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. *Ann Rheum Dis* 2017;76:491–6.
- 30 Senécal J-L, Koenig M, Archambault G, *et al*. Criteria for the pathogenicity of anticentromere (anti-cenp-b) autoantibodies in systemic sclerosis: Comment on the article by van leeuwen *et al*. *Arthritis Rheumatol* 2022;74:1606–7.
- 31 Naparstek Y, Plotz PH. The role of autoantibodies in autoimmune disease. *Annu Rev Immunol* 1993;11:79–104.
- 32 Freire M, Rivera A, Sopeña B, *et al*. Clinical and epidemiological differences between men and women with systemic sclerosis: a study in a Spanish systemic sclerosis cohort and literature review. *Clin Exp Rheumatol* 2017;35 Suppl 106:89–97.
- 33 Tyndall AJ, Bannert B, Vonk M, *et al*. Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. *Ann Rheum Dis* 2010;69:1809–15.